-

Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development

Innovative 6,000-square-foot facility enables clinical and commercial process development support to help cell therapy developers transition from research-scale to commercialization

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, Calif. This advanced facility is designed to accelerate the development and commercialization of cell therapies, specifically by supporting biotech, biopharma and translational customers developing cell-based immunotherapies.

Through this new center, cell therapy developers can leverage Thermo Fisher’s expansive product and technology portfolio and deep process optimization knowledge to create comprehensive, end-to-end manufacturing workflows that can scale to enable clinical and commercial success. This initiative is part of Thermo Fisher’s commitment to advancing life sciences and improving patient outcomes through innovative solutions.

"Our new Advanced Therapies Collaboration Center represents a significant milestone in our ongoing commitment to deliver solutions that address critical challenges in cell therapy development. By enabling access to our expertise and broad range of instrumentation, reagents, lab equipment and analytical solutions, we aim to help our customers overcome manufacturing hurdles and accelerate their path to commercialization," said Betty Woo, vice president, cell, gene and advanced therapies, Thermo Fisher Scientific. "By fostering collaboration and innovation, the center is poised to play a pivotal role in helping to advance cell therapies, ultimately improving patient lives."

Partnering closely with Thermo Fisher, cell therapy developers can receive the essential resources and support they need to transition to Current Good Manufacturing Practices (cGMP manufacturing). This collaboration helps navigate go-to-market obstacles.

Key ATxCC program benefits include:

  • Access to innovative technologies: Developers gain access to Thermo Fisher laboratory equipment and analytical solutions – even before these technologies are available to the broader market. These advanced technologies can streamline manufacturing, help limit contamination risks and promote product consistency.
  • Protocol and process optimization support: Specialized scientists and engineers facilitate support in creating optimized manufacturing processes and protocols utilizing Thermo Fisher products, helping ensure they are scalable and robust.
  • Ongoing support as therapeutic programs evolve: Dedicated regulatory, quality and partnership management teams assist developers in growing and advancing their cell therapy programs by addressing new challenges and enabling platform-specific support.

With collaboration centers already established in Singapore and Korea, Thermo Fisher is thrilled to announce the opening of our Carlsbad center, with an expanded footprint in Philadelphia expected later this year. Both centers are designed to offer clinical and commercial cGMP process development to our valued partners.

For more information about Thermo Fisher’s advanced therapies collaboration center program, please visit www.thermofisher.com/celltherapycollaborations.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Name: Dana Maxwell
Phone: (760) 859-8539
E-mail: dana.maxwell@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Name: Dana Maxwell
Phone: (760) 859-8539
E-mail: dana.maxwell@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom